| Literature DB >> 28420352 |
Adam Steventon1, Sarwat I Chaudhry2, Zhenqiu Lin3, Jennifer A Mattera3, Harlan M Krumholz3.
Abstract
BACKGROUND: Since clinical management of heart failure relies on weights that are self-reported by the patient, errors in reporting will negatively impact the ability of health care professionals to offer timely and effective preventive care. Errors might often result from rounding, or more generally from individual preferences for numbers ending in certain digits, such as 0 or 5. We apply fraud detection methods to assess preferences for numbers ending in these digits in order to inform medical decision making.Entities:
Keywords: Alert fatigue; End-digit preference; Self-report; Telemedicine
Mesh:
Year: 2017 PMID: 28420352 PMCID: PMC5395848 DOI: 10.1186/s12911-017-0426-4
Source DB: PubMed Journal: BMC Med Inform Decis Mak ISSN: 1472-6947 Impact factor: 2.796
Fig. 1Remainders of weight values reported to the telemonitoring system (n = 114,867)
Baseline characteristics of patients with and without end-digit preference. Data show percentages or mean values (95% confidence intervals)
| End-digit preference ( | No end-digit preference ( | |
|---|---|---|
| Mean age in years | 60.1 (56.3 to 64.0) | 64.0 (62.6 to 65.3) |
| Male | 68.6 (55.1 to 83.0) | 55.2 (50.7 to 59.6) |
| New York Heart Association class | ||
| I | 2.6 (0 to 8.3) | 4.0 (2.3 to 5.8) |
| II | 43.6 (30.1 to 56.9) | 35.5 (31.0 to 40.2) |
| III | 45.2 (30.8 to 59.8) | 52.2 (47.4 to 56.5) |
| IV | 8.6 (0.6 to 17.6) | 8.4 (5.8 to 11.2) |
| Race | ||
| White | 54.2 (39.4 to 67.6) | 58.4 (54.2 to 62.4) |
| Black | 18.5 (6.0 to 32.1) | 36.7 (32.5 to 41.1) |
| Other | 27.3 (18.1 to 37.6) | 4.9 (3.0 to 7.2) |
| Hispanic or Latino ethnic group | 0 (0 to 3.6) | 3.0 (1.6 to 4.7) |
| LVEF < 40% | 75.7 (62.4 to 88.5) | 65.8 (61.2 to 70.3) |
| Chronic kidney disease | 59.9 (44.4 to 74.2) | 56.8 (52.3 to 61.5) |
| COPD | 19.6 (8.6 to 31.3) | 20.9 (17.3 to 24.8) |
| Diabetes mellitus | 52.8 (38.9 to 67.9) | 52.2 (47.4 to 56.5) |
| Hypertension | 63.4 (50.6 to 76.8) | 77.0 (73.4 to 81.1) |
| Coronary artery disease | 55.1 (41.4 to 69.3) | 60.1 (55.6 to 64.5) |
| Mean blood pressure | ||
| Systolic | 122.2 (115.3 to 129.0) | 121.4 (119.1 to 123.8) |
| Diastolic | 69.7 (65.8 to 73.7) | 70.2 (69.1 to 71.5) |
| Mean serum potassium | 4.0 (3.9 to 4.2) | 4.1 (4.1 to 4.2) |
| Mean blood urea nitrogen | 31.9 (26.4 to 38.2) | 28.1 (26.4 to 29.9) |
| Mean serum creatinine | 1.6 (1.4 to 1.9) | 1.5 (1.4 to 1.6) |
| Mean weight in lbs. | 165.6 (142.9 to 187.1) | 172.4 (165.8 to 179.4) |
| Medications | ||
| ACE inhibitor or ARB | 73.5 (59.3 to 87.5) | 66.1 (61.7 to 70.6) |
| Aldosterone-receptor antagonist | 41.6 (29.6 to 55.2) | 31.2 (27.1 to 35.5) |
| Beta blocker | 87.0 (76.2 to 96.7) | 82.3 (78.5 to 85.7) |
| Digoxin | 30.2 (17.1 to 42.3) | 24.5 (20.3 to 29.0) |
| Loop diuretic | 82.5 (71.4 to 93.9) | 80.1 (76.2 to 83.6) |
| Graduated high school | 82.0 (70.0 to 94.4) | 75.6 (71.5 to 79.6) |
| Household income < $10,000 pa | 23.6 (9.9 to 37.8) | 22.4 (18.1 to 26.8) |
Alerts triggered by patients with and without end-digit preference during the six-month trial period (95% confidence intervals)
| End-digit preference ( | No end-digit preference ( | |
|---|---|---|
| Mean number of alerts (Tele-HF)a | 2.9 (2.3 to 3.5) | 2.3 (2.2 to 2.5) |
| Mean number of alerts (2 pound)b | 3.2 (2.6 to 3.7) | 2.6 (2.4 to 2.7) |
aA difference of more than three pounds in either direction from the first-recorded weight
bA difference of more than two pounds in either direction from one day to the next
Simulation analysis
| Proportion of telemonitored patients with EDP (%) | Probability of EDP patients to demonstrate this preference (%) | Assignment of EDP patients (%) | Assignment of NEDP patients (%) | Proportion of people in A1-A4 with NEDP (%) | ||
|---|---|---|---|---|---|---|
| A0 | A1-A4 | A0 | A1-A4 | |||
| 15% | 30% | 100.0 | 0.0 | 5.9 | 23.5 | 100.0 |
| 15% | 50% | 100.0 | 0.0 | 6.0 | 23.1 | 100.0 |
| 15% | 70% | 100.0 | 0.0 | 5.6 | 23.4 | 100.0 |
| 30% | 30% | 100.0 | 0.0 | 5.7 | 23.0 | 100.0 |
| 30% | 50% | 100.0 | 0.0 | 5.8 | 23.1 | 100.0 |
| 30% | 70% | 100.0 | 0.0 | 5.8 | 22.7 | 100.0 |
| 60% | 30% | 100.0 | 0.0 | 5.8 | 23.2 | 99.9 |
| 60% | 50% | 100.0 | 0.0 | 6.1 | 23.0 | 100.0 |
| 60% | 70% | 100.0 | 0.0 | 5.5 | 23.1 | 100.0 |
Note: Assumes patients submitted weight readings on 162 days. Based on 10,000 replications of the simulation experiment
Simulation analysis – effect of alternative assumptions for weight progression
| Standard deviation for daily weight change | Assignment of EDP patients (%) | Assignment of NEDP patients (%) | Proportion of people in A1-A4 with NEDP (%) | ||
|---|---|---|---|---|---|
| A0 | A1-A4 | A0 | A1-A4 | ||
| 0 (Weights constant over time) | 100.0 | 79.1 | 20.9 | 79.1 | 85.0 |
| 0.05 | 100.0 | 83.8 | 27.8 | 87.2 | 85.5 |
| 0.1 | 100.0 | 83.9 | 33.2 | 92.6 | 86.2 |
| 0.5 | 100.0 | 10.4 | 24.8 | 75.4 | 97.6 |
| 1.0 | 100.0 | 0.2 | 11.0 | 43.0 | 99.9 |
| Limiting scenario (from Table 1) | 100.0 | 0.0 | 5.9 | 23.5 | 100.0 |
Note: Assumes 15% of patients have EDP, 30% of the time. Patients submitted weight readings on 162 days. Based on 10,000 replications of the simulation experiment
Simulation analysis – effect of alternative assumptions for number of weight readings submitted
| Assignment of EDP patients (%) | Assignment of NEDP patients (%) | Proportion of people in A1-A4 with NEDP (%) | |||
|---|---|---|---|---|---|
| A0 | A1-A4 | A0 | A1-A4 | ||
| 10 | 42.6 | 1.9 | 3.5 | 12.9 | 97.5 |
| 20 | 96.0 | 4.7 | 8.4 | 34.1 | 97.6 |
| 40 | 99.8 | 0.6 | 4.4 | 17.4 | 99.4 |
| 60 | 100.0 | 0.3 | 4.5 | 16.9 | 99.7 |
| 80 | 100.0 | 0.3 | 6.7 | 25.9 | 99.8 |
| 162 (from Table 1) | 100.0 | 0.0 | 5.9 | 23.5 | 100.0 |
| 180 | 100.0 | 0.0 | 6.0 | 22.6 | 100.0 |
Note: Assumes 15% of patients have EDP, 30% of the time, with weights that are uniformly distributed on {0, 1, 2, 3, and 4} modulo 5. Based on 10,000 replications of the simulation experiment
Baseline characteristics of patients in subgroups A0-A4. Data show percentages (numbers of patients) unless stated otherwise
| A0 ( | A1 ( | A2 ( | A3 ( | A4 ( | |
|---|---|---|---|---|---|
| Mean age in years (SD) | 62.1 (13.8) | 66.1 (14.1) | 65.1 (14.2) | 63.1 (14.7) | 62.1 (15.2) |
| Male | 61.8 (131) | 59.4 (57) | 58.9 (63) | 50.8 (66) | 52.6 (50) |
| New York Heart Association class | |||||
| I | 3.3 (7) | 3.1 (3) | 3.7 (4) | 5.4 (7) | 3.2 (3) |
| II | 39.6 (84) | 34.4 (33) | 43.9 (47) | 30.8 (40) | 33.7 (32) |
| III | 48.6 (103) | 54.2 (52) | 45.8 (49) | 52.3 (68) | 56.8 (54) |
| IV | 8.5 (18) | 8.3 (8) | 6.5 (7) | 11.5 (15) | 6.3 (6) |
| Race | |||||
| White | 56.1 (119) | 56.3 (54) | 63.6 (68) | 56.9 (74) | 56.8 (54) |
| Black | 27.8 (59) | 36.5 (35) | 34.6 (37) | 36.9 (48) | 38.9 (37) |
| Other | 16.0 (34) | 7.3 (7) | 1.9 (2) | 6.2 (8) | 4.2 (4) |
| Hispanic or Latino ethnic group | 1.4 (3) | 2.1 (2) | 1.9 (2) | 4.6 (6) | 3.2 (3) |
| LVEF < 40%a | 70.8 (148) | 71.7 (66) | 62.1 (64) | 66.7 (84) | 62.4 (58) |
| Chronic kidney diseaseb | 58.2 (121) | 58.3 (56) | 62.3 (66) | 50.8 (66) | 57.4 (54) |
| COPD | 20.3 (43) | 28.1 (27) | 21.5 (23) | 16.2 (21) | 18.9 (18) |
| Diabetes mellitus | 52.4 (111) | 54.2 (52) | 54.2 (58) | 53.8 (70) | 46.3 (44) |
| Hypertension | 70.3 (149) | 78.1 (75) | 76.6 (82) | 77.7 (101) | 75.8 (72) |
| Coronary artery disease | 57.5 (122) | 63.5 (61) | 56.1 (60) | 61.5 (80) | 58.9 (56) |
| Mean blood pressure (SD) | |||||
| Systolic | 122.1 (23.8) | 122.1 (25.4) | 120.1 (22.5) | 123.1 (24.6) | 121.1 (24.5) |
| Diastolic | 70.1 (13.8) | 70.1 (14.3) | 70.1 (12.2) | 70.1 (13.6) | 71.1 (12.7) |
| Mean serum potassium (SD)c | 4.1 (0.6) | 4.1 (0.5) | 4.1 (0.6) | 4.1 (0.6) | 4.1 (0.5) |
| Mean blood urea nitrogen (SD)d | 30.1 (20.3) | 27.1 (16.3) | 30.1 (16.7) | 28.1 (18.8) | 27.1 (15.4) |
| Mean serum creatinine (SD)e | 2.1 (0.9) | 1.1 (0.8) | 2.1 (0.9) | 1.1 (0.8) | 1.1 (0.7) |
| Mean weight in lbs. (SD) | 169.1 (79.6) | 175.1 (72.5) | 173.1 (76.1) | 170.1 (73.2) | 173.1 (67.3) |
| Medications | |||||
| ACE inhibitor or ARB | 69.8 (148) | 64.6 (62) | 66.4 (71) | 70.0 (91) | 62.1 (59) |
| Aldosterone-receptor antagonist | 36.3 (77) | 31.3 (30) | 29.0 (31) | 33.1 (43) | 31.6 (30) |
| Beta blocker | 84.4 (179) | 84.4 (81) | 80.4 (86) | 82.3 (107) | 82.1 (78) |
| Digoxin | 27.4 (58) | 28.1 (27) | 20.6 (22) | 22.3 (29) | 28.4 (27) |
| Loop diuretic | 81.1 (172) | 79.2 (76) | 79.4 (85) | 83.1 (108) | 77.9 (74) |
| Did not graduate high schoolf | 21.3 (43) | 23.7 (22) | 23.5 (24) | 26.1 (31) | 24.2 (22) |
| Household income < $10,000 pag | 23.1 (39) | 22.4 (17) | 17.3 (14) | 26.9 (28) | 21.3 (16) |
a N = 209, 92, 103, 126, 93
b N = 208, 96, 106, 130, 94
c N = 204, 95, 104, 128, 93
d N = 206, 94, 102, 126, 92
e N = 208, 96, 106, 130, 94
f N = 202, 93, 102, 119, 91
g N = 169, 76, 81, 104, 75